Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases. Furthermore, there were no important safety risks identified among the overall population throughout the four and a half years following vaccination during the phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.
TIDES is a double-blind, randomised, placebo-controlled trial is evaluating the safety and efficacy of two TAK-003 doses. It involves the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.
The new long-term results back-up previously published TIDES data which demonstrated the candidate vaccine met its primary endpoint of overall 80.2% efficacy at the 12-month follow-up, as well as all secondary endpoints for which there were a sufficient number of dengue cases at 18-months follow-up, including 90.4% hospitalised dengue.
“The burden of dengue is far reaching, and over half of the world’s population is at risk of dengue each year,” said Eng Eong Ooi from the Duke-NUS Medical School. “There is an urgent need for impactful prevention tools to combat the disease. The long-term TIDES results indicate that TAK-003 could be an important addition to the limited tools we have to prevent dengue, particularly given the demonstrated protection against hospitalisations.”
“Dengue is a complex, global disease, and the TIDES trial was designed to account for this, including both dengue-naïve and dengue-exposed populations in Latin America and Asia where outbreaks are prevalent, with evaluation over four and a half years,” added Gary Dubin, president, global vaccine business unit at Takeda. “We are proud that the results continue to demonstrate the efficacy and safety of TAK-003 and its ability to provide long-term protection against dengue.”
While the long-term follow-up for the primary two-dose series has been completed, the TIDES trial continues to evaluate the safety and efficacy of a booster dose. TIDES trial is Takeda’s largest interventional clinical trial to date – enrolling more than 20,000 healthy children and adolescents of four to 16 years of age, across eight dengue-endemic countries.
by John Pinching
Source: pharmatimes.com
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
